MAPT and Alzheimer disease: Alzheimer disease (AD), the leading cause of dementia worldwide, is primarily characterized by amyloid-β and tau protein accumulations in the brain.1 Despite the advent of cholinergic enhancement as a cornerstone of AD therapeutics, the recent approval of anti–amyloid monoclonal antibodies has introduced a new era of potential disease-modifying treatments.2 However, given the multifaceted and complex pathophysiological mechanisms underlying AD, there remains a critical need for additional therapeutic approaches to advance clinical management.